As expected, there were no significant differences in the expression of glycolysis pathway genes (i.e. upstream of the PDH complex) between benign tissue and cancer (Table 2), which is consistent with previous reports and reflects the clinical finding that FDG-PET is less effective in imaging prostate malignancy [15] than other cancers. The gene discussed is PDP1; the disease is cancer.